Selected Key Figures

  • Sales

    Key figure Sales (bar chart)Key figure Sales (bar chart) Inactive key figure Sales (bar chart)Inactive key figure Sales (bar chart)
  • EBITDA Before Special Items

    Key figure EBITDA margin (bar chart)Key figure EBITDA margin (bar chart) Inactive key figure EBITDA margin (bar chart)Inactive key figure EBITDA margin (bar chart)
  • Net income

    Inactive key figure Net income (bar chart)Inactive key figure Net income (bar chart) Key figure Net income (bar chart)Key figure Net income (bar chart)

+3.2%

Bayer Group sales increased by 3.2 percent to €11,941 million in the first quarter of 2016 after adjusting for currency and portfolio changes (reported: + 0.5%).

View all Q1 key figures

+15.7%

Group EBITDA before special items improved by a substantial 15.7 percent to €3,404 million. All segments contributed to this increase.

View all Q1 key figures

+13.3%

Net income from continuing and discontinued operations grew by 13.3 percent to around €1,511 million.

View all Q1 key figures

Business Development of the Divisions

Pharmaceuticals

Pharmaceuticals sales rose by a very encouraging 12.2 percent (currency and portfolio adjusted) to €3,889 million in the first quarter of 2016. This was largely attributable to the continued strong development of our recently launched products.

Find out more

Consumer Health

Consumer Health sales rose slightly in the first quarter of 2016, moving forward by 2.2 percent (currency and portfolio adjusted) to €1,520 million. The business posted significant gains in Latin America / Africa / Middle East and in Asia / Pacific, while sales were down in Europe due mainly to the macroeconomic situation in Russia.

Find out more

Crop Science

Crop Science sales moved ahead by 1.2 percent (currency and portfolio adjusted) to €3,023 million in the first quarter of 2016. We slightly expanded business at Crop Protection / Seeds despite an ongoing weak market environment.

Find out more